Non-small cell lung cancer
Conditions
Interventions
Vinorelbine 25mg/m2Day1,8 Bevacizumab 15mg/m2 Day1 3-6 cycle 21days as one cycle
Sponsors
Toho University Omori Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)StageIIIB/IV non-small-cell lung cancer(non-squamous cell carcinoma) 2)Age>=70 3)ECOG performance status 0-1 4) With one or more measurable disease 5)Patients who have previously treated chemotherapy, radiotherapy, immunotherapy regimen (without bevacizumab and vinorelbine). 6) No problem adequate organ function. 7)A life expectancy of more than 3 months. 8)All patients provided written informed consent before initiation of study-related procedures.
Exclusion criteria
Exclusion criteria: 1) Receiving a blood transfusion, hematopoietic factor, anticoagulant drug 2 weeks prior to enrollment. 2) Severe renal function disorder 2+ or higher proteinuria within 2 weeks prior to enrollment. 3) Serious drug allergy. 4) Active synchronous malignancies. 5) Uncontrolled Active infection. 6) Uncontrollable hypertension, uncontrollable diabetes. 7) Clinically significant heart disease. 8)Thromboembolism, interstitial pneumonia, pulmonary fibrosis and severe emphysema within the past one year. 9)Traumatic fracture of unrecovery 10) Mental disorder, central nervous system disorders, cerebrovascular disorders. 11) Permeation of the neoplastic cell in large vessels. 12) Hollowing out of the tumor. 13) Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment completion | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety Efficacy QOL OS PFS | — |
Countries
Japan
Contacts
Public ContactKazutoshi Isobe
Toho University Omori Medical Center Department of Respiratory Medicine
Outcome results
None listed